Maria-Luisa Maccecchini
Chief Executive Officer at ANNOVIS BIO, INC.
Net worth: 13 M $ as of 2024-03-30
Profile
Maria-Luisa Maccecchini is the founder.
She founded Annovis Bio, Inc. in 2008, where she currently holds the title of President, CEO, CFO & Director.
She also founded Annovis, Inc. in 1992, where she served as the Chief Executive Officer from 1992 to 2001.
Dr. Maccecchini is also the founder of Message Pharmaceuticals, Inc. Dr. Maccecchini's current job(s) include being an Independent Director at Treventis Corp., Lantern Pharma, Inc., and Translational Development Acquisition Corp.
Her former job positions include being a Director at Protez Pharmaceuticals, Inc., a Director & Partner at Mid-Atlantic Angel Group, the Head-Molecular Biology at Mallinckrodt, Inc.(Old), a Member at Robin Hood Ventures, and the General Manager at Bachem Bioscience, Inc. She also held the position of Head-Molecular Biology at Mallinckrodt LLC.
Dr. Maccecchini obtained her doctorate degree from The Rockefeller University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ANNOVIS BIO INC
9.98% | 2023-11-19 | 1,098,459 ( 9.98% ) | 13 M $ | 2024-03-30 |
LANTERN PHARMA, INC.
-.--% | 2023-04-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Maria-Luisa Maccecchini active positions
| Companies | Position | Start |
|---|---|---|
| ANNOVIS BIO, INC. | Chief Executive Officer | 2008-04-30 |
| LANTERN PHARMA INC. | Director/Board Member | 2022-06-07 |
Treventis Corp.
 Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Translational Development Acquisition Corp.
 Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Maria-Luisa Maccecchini
| Companies | Position | End |
|---|---|---|
Robin Hood Ventures
 Robin Hood Ventures Investment ManagersFinance Robin Hood Ventures (RHV) is a venture capital firm founded in 1999 by Rob weber. The firm is headquartered in Philadelphia, Pennsylvania. | Private Equity Investor | 2008-11-29 |
Annovis, Inc.
 Annovis, Inc. Chemicals: SpecialtyProcess Industries Annovis, Inc. develops, manufactures, and markets a wide variety of nucleic acid based for the life sciences sector. The company is headquartered in Aston, PA. | Chief Executive Officer | 2000-12-31 |
Message Pharmaceuticals, Inc.
 Message Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Message Pharmaceuticals, Inc. develops pharmaceutical drugs. It operates as research development company involved in RNA research and exploring other types of RNAs to look for RNA-binding proteins, especially to combat RNA viruses and to treat all major disease categories. Message Pharmaceuticals was founded in 2002 and is located in Malvern, PA | Chief Executive Officer | - |
Mallinckrodt LLC
 Mallinckrodt LLC Pharmaceuticals: MajorHealth Technology Mallinckrodt LLC is proud to be one of the world's largest suppliers of both controlled substance pain medication and acetaminophen and to have over a century of leadership in helping to diagnose disease through imaging procedures. They are focused on innovative research and development programs, strong clinician relationships and a collaborative approach to new business opportunities. In short, they aim to lead a new generation of patient care by pursuing better, safer, more cost effective ways of diagnosing and treating disease to improve patient outcomes. | Corporate Officer/Principal | - |
| Bachem Bioscience, Inc. | Corporate Officer/Principal | - |
Training of Maria-Luisa Maccecchini
| The Rockefeller University | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ANNOVIS BIO, INC. | Health Technology |
| LANTERN PHARMA INC. | Health Technology |
| Private companies | 10 |
|---|---|
Mallinckrodt, Inc.(Old)
 Mallinckrodt, Inc.(Old) Medical SpecialtiesHealth Technology Mallinckrodt, Inc. developed manufactured and marketed medical products for hospitals. It provided specialty healthcare products for diagnostic imaging, respiratory care and pain relief. The firm sold its products to hospitals, alternate care sites, drug manufacturers and clinical laboratories. The company was founded in 1867 and was headquartered in Hazelwood, MO. | Health Technology |
Annovis, Inc.
Annovis, Inc. Chemicals: SpecialtyProcess Industries Annovis, Inc. develops, manufactures, and markets a wide variety of nucleic acid based for the life sciences sector. The company is headquartered in Aston, PA. | Process Industries |
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Robin Hood Ventures
Robin Hood Ventures Investment ManagersFinance Robin Hood Ventures (RHV) is a venture capital firm founded in 1999 by Rob weber. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Mid-Atlantic Angel Group
 Mid-Atlantic Angel Group Investment ManagersFinance Mid-Atlantic Angel Group operates as a alternative investment manager. The company is headquartered in Philadelphia, PA. | Finance |
Message Pharmaceuticals, Inc.
Message Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Message Pharmaceuticals, Inc. develops pharmaceutical drugs. It operates as research development company involved in RNA research and exploring other types of RNAs to look for RNA-binding proteins, especially to combat RNA viruses and to treat all major disease categories. Message Pharmaceuticals was founded in 2002 and is located in Malvern, PA | Health Technology |
| Bachem Bioscience, Inc. | |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Health Technology |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | Finance |
Mallinckrodt LLC
Mallinckrodt LLC Pharmaceuticals: MajorHealth Technology Mallinckrodt LLC is proud to be one of the world's largest suppliers of both controlled substance pain medication and acetaminophen and to have over a century of leadership in helping to diagnose disease through imaging procedures. They are focused on innovative research and development programs, strong clinician relationships and a collaborative approach to new business opportunities. In short, they aim to lead a new generation of patient care by pursuing better, safer, more cost effective ways of diagnosing and treating disease to improve patient outcomes. | Health Technology |
- Stock Market
- Insiders
- Maria-Luisa Maccecchini
